Scott Grabine
Barclays Bank PLC, Research Division

We're all fired up and ready to go. Well, good morning, and thank you for joining us for our Bausch fireside chat. My name is Scott Grabine, and I'm a high-yield healthcare analyst at Barclays. Participating from Bausch today, we have Will Woodfield and Garen Sarafian. Thanks so much, guys, for joining us, and great to see you down in Austin again.

William Woodfield
Senior VP & Treasurer

Yes. Thanks for having us. Pleasure...

Garen Sarafian
VP & Head of Investor Relations

Good to be here.

Scott Grabine
Barclays Bank PLC, Research Division

Yes. So 12 consecutive quarters now with growth in revenue and EBITDA. Maybe we can start by just talking about what's worked so well for the company in general and more recently, in particular.

William Woodfield
Senior VP & Treasurer

Yes, happy to talk about that. So we are extremely proud of our record of 12 quarters in a row of top line and bottom line growth, and we hope to continue that streak moving forward. We have been really focused on top line growth, even better bottom line growth and even better cash flow. That's the -- that's how we view the company. And so a large part of that has been to do with performance, especially in our Salix and Xifaxan business as well as our Solta business and also international.

And so we can get into all of those when we talk today. I would start with Salix, especially. Salix has been